{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:41:05Z","timestamp":1713195665313},"posted":{"date-parts":[[2023,12,28]]},"group-title":"In Review","reference-count":41,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Friedreich\u2019s ataxia is a degenerative and progressive multisystem disorder caused by mutations in the highly conserved frataxin (FXN) gene that results in FXN protein deficiency and mitochondrial dysfunction. While gene therapy approaches are promising, consistent induction of therapeutic FXN protein expression that is sub-toxic has proven challenging, and numerous therapeutic approaches are being tested in animal models. FXN (hFXN in humans, mFXN in mice) is proteolytically modified in mitochondria to produce mature FXN. However, unlike endogenous hFXN, endogenous mFXN is further processed into N-terminally truncated, extra-mitochondrial mFXN forms of unknown function. This study assessed mature exogenous hFXN expression levels in the heart and liver of C57Bl\/6 mice 7\u201310 months after intravenous administration of a recombinant adeno-associated virus encoding hFXN (AAVrh.10hFXN) and examined the potential for hFXN truncation in mice. AAVrh.10hFXN induced dose-dependent expression of hFXN in the heart and liver. Interestingly, hFXN was processed into truncated forms, but found at lower levels than mature hFXN. However, the truncations were at different positions than mFXN. AAVrh.10hFXN induced mature hFXN expression in mouse heart and liver at levels that approximated endogenous mFXN levels. These results demonstrate that AAVrh.10hFXN may induce expression of therapeutic levels of mature hFXN in mice.<\/jats:p>","DOI":"10.21203\/rs.3.rs-3788652\/v1","type":"posted-content","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T06:35:23Z","timestamp":1703745323000},"source":"Crossref","is-referenced-by-count":0,"title":["Expression and processing of mature human frataxin after gene therapy in mice"],"prefix":"10.21203","author":[{"given":"Teerapat","family":"Rojsajjakul","sequence":"first","affiliation":[{"name":"University of Pennsylvania Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithya","family":"Selvan","sequence":"additional","affiliation":[{"name":"LEXEO Therapeutics, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishnu","family":"De","sequence":"additional","affiliation":[{"name":"Weill Cornell College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan B.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Weill Cornell College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Kaminsky","sequence":"additional","affiliation":[{"name":"Weill Cornell College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolan","family":"Sondhi","sequence":"additional","affiliation":[{"name":"Weill Cornell College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Janki","sequence":"additional","affiliation":[{"name":"LEXEO Therapeutics, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[{"name":"Weill Cornell College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clementina","family":"Mesaros","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richie","family":"Khanna","sequence":"additional","affiliation":[{"name":"LEXEO Therapeutics, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/ars.2009.3015","article-title":"Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities","volume":"13","author":"Santos R","year":"2010","unstructured":"Santos, R. et al. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 13, 651\u2013690 (2010). https:\/\/doi.org\/10.1089\/ars.2009.3015","journal-title":"Antioxid Redox Signal"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub4","article-title":"Pharmacological treatments for Friedreich ataxia","volume":"CD007791","author":"Kearney M","year":"2016","unstructured":"Kearney, M., Orrell, R. W., Fahey, M., Brassington, R. & Pandolfo, M. Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev, CD007791 (2016). https:\/\/doi.org\/10.1002\/14651858.CD007791.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1302\/0301-620X.94B5.28391","article-title":"Scoliosis in patients with Friedreich's ataxia","volume":"94","author":"Tsirikos AI","year":"2012","unstructured":"Tsirikos, A. I. & Smith, G. Scoliosis in patients with Friedreich's ataxia. J Bone Joint Surg Br 94, 684\u2013689 (2012). https:\/\/doi.org\/10.1302\/0301-620X.94B5.28391","journal-title":"J Bone Joint Surg Br"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1212\/NXG.0000000000000683","article-title":"Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia","volume":"8","author":"Rodden LN","year":"2022","unstructured":"Rodden, L. N., Rummey, C., Dong, Y. N. & Lynch, D. R. Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia. Neurol Genet 8, e683 (2022). https:\/\/doi.org\/10.1212\/NXG.0000000000000683","journal-title":"Neurol Genet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2015.05.074","article-title":"The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvement","volume":"194","author":"Weidemann F","year":"2015","unstructured":"Weidemann, F. et al. The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvement. Int J Cardiol 194, 50\u201357 (2015). https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.074","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/archdischild-2021-322455","article-title":"Friedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study","volume":"107","author":"Norrish G","year":"2022","unstructured":"Norrish, G. et al. Friedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Arch Dis Child 107, 450\u2013455 (2022). https:\/\/doi.org\/10.1136\/archdischild-2021-322455","journal-title":"Arch Dis Child"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou AY","year":"2011","unstructured":"Tsou, A. Y. et al. Mortality in Friedreich ataxia. J Neurol Sci 307, 46\u201349 (2011). https:\/\/doi.org\/10.1016\/j.jns.2011.05.023","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","article-title":"A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia","volume":"72","author":"Pousset F","year":"2015","unstructured":"Pousset, F. et al. A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. JAMA Neurol 72, 1334\u20131341 (2015). https:\/\/doi.org\/10.1001\/jamaneurol.2015.1855","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich Ataxia","volume":"26","author":"Piguet F","year":"2018","unstructured":"Piguet, F. et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich Ataxia. Mol Ther 26, 1940\u20131952 (2018). https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.006","journal-title":"Mol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041815","article-title":"Future Prospects of Gene Therapy for Friedreich's Ataxia","volume":"22","author":"Ocana-Santero G","year":"2021","unstructured":"Ocana-Santero, G., Diaz-Nido, J. & Herranz-Martin, S. Future Prospects of Gene Therapy for Friedreich's Ataxia. Int J Mol Sci 22 (2021). https:\/\/doi.org\/10.3390\/ijms22041815","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"903139","DOI":"10.3389\/fgeed.2022.903139","article-title":"Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia","volume":"4","author":"Sivakumar A","year":"2022","unstructured":"Sivakumar, A. & Cherqui, S. Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia. Front Genome Ed 4, 903139 (2022). https:\/\/doi.org\/10.3389\/fgeed.2022.903139","journal-title":"Front Genome Ed"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/10409230600846058","article-title":"The structure and function of frataxin","volume":"41","author":"Bencze KZ","year":"2006","unstructured":"Bencze, K. Z. et al. The structure and function of frataxin. Crit Rev Biochem Mol Biol 41, 269\u2013291 (2006). https:\/\/doi.org\/10.1080\/10409230600846058","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"Suppl 1","key":"ref13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jnc.12220","article-title":"Frataxin: a protein in search for a function","volume":"126","author":"Pastore A","year":"2013","unstructured":"Pastore, A. & Puccio, H. Frataxin: a protein in search for a function. J Neurochem 126 Suppl 1, 43\u201352 (2013). https:\/\/doi.org\/10.1111\/jnc.12220","journal-title":"J Neurochem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano V","year":"1996","unstructured":"Campuzano, V. et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423\u20131427 (1996).","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano V","year":"1997","unstructured":"Campuzano, V. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6, 1771\u20131780 (1997).","journal-title":"Hum Mol Genet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"874768","DOI":"10.3389\/fnins.2022.874768","article-title":"Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood","volume":"16","author":"Wang Q","year":"2022","unstructured":"Wang, Q. et al. Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood. Front Neurosci 16, 874768 (2022). https:\/\/doi.org\/10.3389\/fnins.2022.874768","journal-title":"Front Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1021\/acs.analchem.3c00091","article-title":"Liquid Chromatography-Mass Spectrometry Analysis of Frataxin Proteoforms in Whole Blood as Biomarkers of the Genetic Disease Friedreich's Ataxia","volume":"95","author":"Rojsajjakul T","year":"2023","unstructured":"Rojsajjakul, T. et al. Liquid Chromatography-Mass Spectrometry Analysis of Frataxin Proteoforms in Whole Blood as Biomarkers of the Genetic Disease Friedreich's Ataxia. Anal Chem 95, 4251\u20134260 (2023). https:\/\/doi.org\/10.1021\/acs.analchem.3c00091","journal-title":"Anal Chem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.bbamcr.2012.05.009","article-title":"The role of mitochondria in cellular iron\u2013sulfur protein biogenesis and iron metabolism","volume":"1823","author":"Lill R","year":"2012","unstructured":"Lill, R. et al. The role of mitochondria in cellular iron\u2013sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 1823, 1491\u20131508 (2012). https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.bbamcr.2012.05.009","journal-title":"Biochim Biophys Acta"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/ncomms6013","article-title":"Functional reconstitution of mitochondrial Fe\/S cluster synthesis on Isu1 reveals the involvement of ferredoxin","volume":"5","author":"Webert H","year":"2014","unstructured":"Webert, H. et al. Functional reconstitution of mitochondrial Fe\/S cluster synthesis on Isu1 reveals the involvement of ferredoxin. Nat Commun 5, 5013 (2014). https:\/\/doi.org\/10.1038\/ncomms6013","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40673-017-0062-x","article-title":"Friedreich Ataxia: current status and future prospects","volume":"4","author":"B\u00fcrk K","year":"2017","unstructured":"B\u00fcrk, K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias 4, 4 (2017). https:\/\/doi.org\/10.1186\/s40673-017-0062-x","journal-title":"Cerebellum Ataxias"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24249","article-title":"I. Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length","volume":"76","author":"Chutake YK","year":"2014","unstructured":"Chutake, Y. K., Lam, C., Costello, W. N., Anderson, M. & Bidichandani, S. I. Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length. Ann Neurol 76, 522\u2013528 (2014). https:\/\/doi.org\/10.1002\/ana.24249","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich's ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook A","year":"2017","unstructured":"Cook, A. & Giunti, P. Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull 124, 19\u201330 (2017). https:\/\/doi.org\/10.1093\/bmb\/ldx034","journal-title":"Br Med Bull"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuint.2017.08.002","article-title":"L.-H. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia","volume":"117","author":"Chiang S","year":"2018","unstructured":"Chiang, S., Kalinowski, D. S., Jansson, P. J., Richardson, D. R. & Huang, M. L.-H. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia. Neurochem Int. 117, 35\u201348 (2018).","journal-title":"Neurochem Int."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1038\/s41598-022-09002-5","article-title":"DNA methylation in Friedreich ataxia silences expression of frataxin isoform E","volume":"12","author":"Rodden LN","year":"2022","unstructured":"Rodden, L. N. et al. DNA methylation in Friedreich ataxia silences expression of frataxin isoform E. Sci Rep 12, 5031 (2022). https:\/\/doi.org\/10.1038\/s41598-022-09002-5","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","article-title":"High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models","volume":"19","author":"Belbellaa B","year":"2020","unstructured":"Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L. & Puccio, H. High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models. Mol Ther Methods Clin Dev 19, 120\u2013138 (2020). https:\/\/doi.org\/10.1016\/j.omtm.2020.08.018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","article-title":"In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency","volume":"24","author":"Huichalaf C","year":"2022","unstructured":"Huichalaf, C. et al. In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol Ther Methods Clin Dev 24, 367\u2013378 (2022). https:\/\/doi.org\/10.1016\/j.omtm.2022.02.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0167-4889(02)00265-3","article-title":"Mitochondrial processing peptidases","volume":"1592","author":"Gakh O","year":"2002","unstructured":"Gakh, O., Cavadini, P. & Isaya, G. Mitochondrial processing peptidases. Biochim Biophys Acta 1592, 63\u201377 (2002). https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0167-4889(02)00265-3","journal-title":"Biochim Biophys Acta"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/hmg\/ddm102","article-title":"In vivo maturation of human frataxin","volume":"16","author":"Condo I","year":"2007","unstructured":"Condo, I. et al. In vivo maturation of human frataxin. Hum Mol Genet. 16, 1534\u20131540 (2007).","journal-title":"Hum Mol Genet."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn244%J","author":"Schmucker S","year":"2008","unstructured":"Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. & Puccio, H. The in vivo mitochondrial two-step maturation of human frataxin. Hum Mol Genet. 17, 3521\u20133531 (2008). https:\/\/doi.org\/10.1093\/hmg\/ddn244%J Human Molecular Genetics"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"17043","DOI":"10.1038\/s41598-018-35346-y","article-title":"Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes","volume":"8","author":"Guo L","year":"2018","unstructured":"Guo, L. et al. Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes. Sci Rep. 8, 17043 (2018). https:\/\/doi.org\/10.1038\/s41598-018-35346-y","journal-title":"Sci Rep."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"15788","DOI":"10.1038\/s41598-020-72884-w","article-title":"Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich's ataxia","volume":"10","author":"Weng L","year":"2020","unstructured":"Weng, L. et al. Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich's ataxia. Sci Rep 10, 15788 (2020). https:\/\/doi.org\/10.1038\/s41598-020-72884-w","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1021\/acs.analchem.7b04590","article-title":"Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich's Ataxia","volume":"90","author":"Guo L","year":"2018","unstructured":"Guo, L. et al. Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich's Ataxia. Anal Chem. 90, 2216\u20132223 (2018). https:\/\/doi.org\/10.1021\/acs.analchem.7b04590","journal-title":"Anal Chem."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s42003-023-05472-z","article-title":"Quantification of human mature frataxin protein expression in nonhuman primate hearts after gene therapy","volume":"6","author":"Rojsajjakul T","year":"2023","unstructured":"Rojsajjakul, T. et al. Quantification of human mature frataxin protein expression in nonhuman primate hearts after gene therapy. Commun Biol 6, 1093 (2023). https:\/\/doi.org\/10.1038\/s42003-023-05472-z","journal-title":"Commun Biol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean B","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968 (2010). https:\/\/doi.org\/10.1093\/bioinformatics\/btq054","journal-title":"Bioinformatics"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e47847","DOI":"10.1371\/journal.pone.0047847","article-title":"Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia","volume":"7","author":"Xia H","year":"2012","unstructured":"Xia, H. et al. Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia. PLoS One 7, e47847 (2012). https:\/\/doi.org\/10.1371\/journal.pone.0047847","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia","volume":"20","author":"Perdomini M","year":"2014","unstructured":"Perdomini, M. et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat Med 20, 542\u2013547 (2014). https:\/\/doi.org\/10.1038\/nm.3510","journal-title":"Nat Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1089\/hum.2019.363","article-title":"Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy","volume":"31","author":"Salami CO","year":"2020","unstructured":"Salami, C. O. et al. Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. Hum Gene Ther 31, 819\u2013827 (2020). https:\/\/doi.org\/10.1089\/hum.2019.363","journal-title":"Hum Gene Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","article-title":"In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency","volume":"24","author":"Huichalaf C","year":"2022","unstructured":"Huichalaf, C. et al. In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol Ther Methods Clin Dev 24, 367\u2013378 (2022). https:\/\/doi.org\/10.1016\/j.omtm.2022.02.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1093\/hmg\/ddm163","article-title":"Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues","volume":"16","author":"Martelli A","year":"2007","unstructured":"Martelli, A. et al. Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet 16, 2651\u20132658 (2007). https:\/\/doi.org\/10.1093\/hmg\/ddm163","journal-title":"Hum Mol Genet"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"12142","DOI":"10.1073\/pnas.93.22.12142","article-title":"The N-end rule: functions, mysteries, uses","volume":"93","author":"Varshavsky A","year":"1996","unstructured":"Varshavsky, A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci U S A 93, 12142\u201312149 (1996). https:\/\/doi.org\/10.1073\/pnas.93.22.12142","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/hum.2023.020","article-title":"Identification of Safe and Effective Intravenous Dose of AAVrh.10hFXN to Treat the Cardiac Manifestations of Friedreich's Ataxia","volume":"34","author":"Munoz-Zuluaga C","year":"2023","unstructured":"Munoz-Zuluaga, C. et al. Identification of Safe and Effective Intravenous Dose of AAVrh.10hFXN to Treat the Cardiac Manifestations of Friedreich's Ataxia. Hum Gene Ther 34, 605\u2013615 (2023). https:\/\/doi.org\/10.1089\/hum.2023.020","journal-title":"Hum Gene Ther"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3788652\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3788652\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:16:48Z","timestamp":1713194208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3788652\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3788652\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-024-59060-0","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,12,28]]},"subtype":"preprint"}}